The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
By BZ Group
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by BZ Group
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 149
Description
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.
| Episode | Date |
|---|---|
|
Biohaven Faces FDA Enrollment Hold & AbbVie Reports Menstrual Migraine Results
|
Sep 11, 2026 |
|
Bayer's Hyrnuo Enters First-Line Rivalry & FDA Gets Permanent Center Chiefs
|
Sep 10, 2026 |
|
Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles
|
Sep 09, 2026 |
|
Novo Ends Two Ziltivekimab Heart-Failure Trials & SynAct Plans Another Arthritis Trial
|
Sep 08, 2026 |
|
Week in Review | Bristol's CAR-T Pause Was Three Months Old Before the Public Heard
|
Sep 07, 2026 |
|
Novartis's Pelacarsen Misses—What's Next for Rivals? & FDA Approves Etcamah Before Progression
|
Sep 05, 2026 |
|
AbbVie's Etentamig Clears Phase 3 Myeloma Trial on Both Endpoints & GSK Pays HUTCHMED $110M Upfront for KRAS-EGFR Drug
|
Sep 04, 2026 |
|
uniQure Files Huntington's Gene Therapy — FDA Reversed Twice Already
|
Sep 03, 2026 |
|
Alumis TYK2 Pill Fails Lupus: What's Left of the Platform & Kazia's PI3K Inhibitor Cuts CRC Tumor Burden 52%
|
Sep 02, 2026 |
|
Novartis, BMS Halt Autoimmune CAR-T Trials on Safety & FDA Clears Takeda's Mimrylo in Polycythemia Vera
|
Sep 01, 2026 |
|
Week in Review | AstraZeneca's Wainua Missed in ATTR-CM: The Stabilizer Problem
|
Aug 31, 2026 |
|
Cytokinetics Wins Non-Obstructive HCM, Stock Falls Anyway & Teva bids $57.5M for BioXcel asset as shares collapse 66%
|
Aug 29, 2026 |
|
Roivant's JAK1/TYK2 Pill Wins First Dermatomyositis Nod & Spyre Deprioritizes TL1A Drug After RA Miss
|
Aug 28, 2026 |
|
Revolution Medicines' RAS Inhibitor Cleared in Five Weeks & Spyre's TL1A Antibody Misses in Rheumatoid Arthritis
|
Aug 27, 2026 |
|
Jazz’s HER2 Bispecific Wins First-Line Gastric & McKesson Pays $2.25B for Precision Medicine
|
Aug 26, 2026 |
|
Regenxbio Plunges 26% as FDA Halts Hunter Gene Therapy & Capricor Duchenne Decision Slips to Nov. 22 on Narrower Label
|
Aug 24, 2026 |
|
Week in Review | AstraZeneca Kills Volrustomig Lung Trial, Discloses No Data
|
Aug 23, 2026 |
|
Akeso's Third ADC: What "Differentiated" Still Has to Prove & Leads Biolabs Puts 4-1BB Back on the Board
|
Aug 22, 2026 |
|
Daily Roundup | Moderna and Merck's mRNA Cancer Vaccine Wins Phase 3 — But There's No Filing Date
|
Aug 21, 2026 |
|
Daily Roundup | Heidi Overton FDA Pick: What It Means for Approvals
|
Aug 20, 2026 |
|
Daily Roundup | Amylyx Avexitide Wins Phase 3: 55% Fewer Hypoglycemic Events, Filing at Stake
|
Aug 19, 2026 |
|
Daily Roundup | EyePoint Crashes 67% After Duravyu Fails Phase 3 in Wet AMD
|
Aug 18, 2026 |
|
Week in Review | Lilly's Retatrutide Lawsuits: Enforcing a Drug Nobody Has Approved
|
Aug 17, 2026 |
|
Daily Roundup | Zenbexus Approval Tests a New Endpoint: What BMS Still Owes the FDA
|
Aug 14, 2026 |
|
Daily Roundup | Taiho and Cullinan Stop Lung Cancer Trial Early — Data Too Good to Stay Blinded
|
Aug 13, 2026 |
|
Daily Roundup | Definium's LSD Pill Wins Phase 3 in Anxiety — What It Means for Psychiatry
|
Aug 13, 2026 |
|
Daily Roundup | WuXi AppTec Wins Injunction: Pentagon's Military Label Halted for Now
|
Aug 12, 2026 |
|
Daily Roundup | Jazz Buys Actio Biosciences in $1.3B Rare Epilepsy Deal
|
Aug 10, 2026 |
|
Week in Review | Takeda's Orzeyful Approval Opens the Orexin Market — and a Payer Fight
|
Aug 09, 2026 |
|
Daily Roundup | Vedanta's $60M Lifeline: What VE303 Must Prove in C. diff Phase 3
|
Aug 08, 2026 |
|
Daily Roundup | Replimune Wins FDA Approval for Melanoma Drug After Two Rejections
|
Aug 07, 2026 |
|
Daily Roundup | Merck's 2028 Keytruda Cliff: The Oral PCSK9 Bet
|
Aug 05, 2026 |
|
Daily Roundup | Curium Buys Lantheus for Up to $8B in Cash-and-CVR Deal
|
Aug 03, 2026 |
|
Week in Review | AstraZeneca, Bristol Myers Squibb Weigh a $400B Merger
|
Aug 03, 2026 |
|
Daily Roundup | Novo Nordisk's ZEUS Failure: The Inflammation Thesis Just Got Repriced
|
Aug 01, 2026 |
|
Daily Roundup | Replimune Wins 10-3 FDA Panel Vote for Melanoma Drug RP1
|
Jul 31, 2026 |
|
Daily Roundup | Capricor's Duchenne Cell Therapy Voted Down — What It Means for the Field
|
Jul 30, 2026 |
|
Daily Roundup | Replimune RP1 on the Brink: FDA Calls Melanoma Data Uninterpretable
|
Jul 29, 2026 |
|
Daily Roundup | Capricor Craters 67% as FDA Questions Deramiocel Data
|
Jul 28, 2026 |
|
Week in Review | Amgen Refuses to Pull Tavneos: FDA Showdown Lands Wednesday
|
Jul 26, 2026 |
|
Daily Roundup | Novo Seeks Injunction on Lilly Obesity Ads: The Comparative Claims Precedent
|
Jul 25, 2026 |
|
Daily Roundup | J&J Bispecific Combo Cuts Myeloma Progression Risk 89%
|
Jul 24, 2026 |
|
Daily Roundup | GSK Wins First Lung Cancer Approval — Jideytro Validates a $10.6B Bet
|
Jul 23, 2026 |
|
Daily Roundup | Novo Sues Lilly Over GLP-1 Ads: The Dose-Comparison Fight That Could Rewrite Obesity Marketing
|
Jul 22, 2026 |
|
Daily Roundup | Tempus AI Buys Personalis for $1.5B in MRD Cancer Push
|
Jul 21, 2026 |
|
Week in Review | GSK Kills Camlipixant: The P2X3 Cough Bet Just Went to Zero
|
Jul 19, 2026 |
|
Daily Roundup | GSK Kills Camlipixant: The $2B Bellus Bet Unravels
|
Jul 18, 2026 |
|
Daily Roundup | Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer
|
Jul 16, 2026 |
|
Daily Roundup | Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target
|
Jul 15, 2026 |
|
Daily Roundup | GSK to File Jemperli in Rectal Cancer After Phase 2 Win
|
Jul 14, 2026 |
|
Week in Review | AstraZeneca's Wainua Stumbles: The Clinic Pushed Back on Pharma's Deal Boom
|
Jul 13, 2026 |
|
Daily Roundup | GSK Ends Alector Neuroscience Bet: What the $2.2B Unwind Signals
|
Jul 11, 2026 |
|
Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20%
|
Jul 10, 2026 |
|
Daily Roundup | FDA Halts Drug Rejection Letters — What It Means for Competitive Intel
|
Jul 09, 2026 |
|
Daily Roundup | Vera's TRUTAKNA Wins FDA Nod: The eGFR Readout That Decides the IgAN Race
|
Jul 08, 2026 |
|
Daily Roundup | Vertex Buys Crinetics for $10B in Endocrinology Push
|
Jul 07, 2026 |
|
Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing
|
Jul 04, 2026 |
|
Roche Divarasib Beats Both KRAS G12C Rivals in Phase 3 Lung Cancer Study
|
Jul 04, 2026 |
|
July 01, 2026| Tregzi Approved — Orca Bio Opens a New Lane in Cell Therapy
|
Jul 02, 2026 |
|
Jun 30, 2026 | NEJM Retracts Tavneos Pivotal Trial; Ionis Tryngolza PDUFA Today
|
Jul 01, 2026 |
|
Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye Disease; Merck KGaA's $11.3B Bio-Techne Deal
|
Jun 27, 2026 |
|
Jun 25, 2026 | Ionis Tryngolza FDA Label Expansion Hits Commercial Inflection
|
Jun 26, 2026 |
|
Jun 24, 2026 | FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal
|
Jun 25, 2026 |
|
Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification
|
Jun 24, 2026 |
|
Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China
|
Jun 23, 2026 |
|
Jun 19, 2026 | US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel
|
Jun 20, 2026 |
|
Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM
|
Jun 19, 2026 |
|
Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal
|
Jun 18, 2026 |
|
Jun 16, 2026 | BridgeBio BBP-418 Sweeps LGMD Phase 3; FDA Scrutinizes Moderna Flu Vaccine
|
Jun 17, 2026 |
|
Jun 15, 2026 | CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head
|
Jun 16, 2026 |
|
EHA 2026 Special — Full Meeting Recap
|
Jun 15, 2026 |
|
Jun 12, 2026 | FDA Approves Merck Welireg-Keytruda for Kidney Cancer; Jazz Zepzelca Phase 3 Fails
|
Jun 13, 2026 |
|
Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering
|
Jun 12, 2026 |
|
Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3
|
Jun 11, 2026 |
|
ADA 2026 Special: The full recap
|
Jun 11, 2026 |
|
The AI Vendor Draft — How Big Pharma Picked Its AI Partners | The Pharma Closeout Special Report
|
Jun 08, 2026 |
|
Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data
|
Jun 08, 2026 |
|
Jun 04, 2026 | SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death
|
Jun 05, 2026 |
|
ASCO 2026 Special, Part 2 — ThClosing Days: Iza-bren Doubles Down in TNBC & Esophageal
|
Jun 03, 2026 |
|
ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS
|
Jun 01, 2026 |
|
May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS
|
Jun 01, 2026 |
|
May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3
|
May 30, 2026 |
|
May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B
|
May 29, 2026 |
|
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
|
May 21, 2026 |
|
May 19, 2026 | Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head
|
May 21, 2026 |
|
May 18, 2026 | Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA
|
May 19, 2026 |
|
May 15, 2026 | FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval
|
May 17, 2026 |
|
May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang
|
May 15, 2026 |
|
May 13, 2026 | BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs
|
May 14, 2026 |
|
May 12, 2026 | FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance
|
May 13, 2026 |
|
May 11, 2026 | CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low
|
May 12, 2026 |
|
May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal
|
May 11, 2026 |
|
May 08, 2026 | Trump Plans to Fire FDA Commissioner Makary; Leqembi SC Delayed to August
|
May 09, 2026 |
|
May 07, 2026 | Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI
|
May 08, 2026 |
|
May 06, 2026 | Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1
|
May 07, 2026 |
|
May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off
|
May 05, 2026 |
|
May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval
|
May 05, 2026 |
|
May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos
|
May 04, 2026 |
|
May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1
|
May 04, 2026 |
|
Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal
|
Apr 29, 2026 |
|
Apr 27, 2026 | Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon
|
Apr 28, 2026 |
|
Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B
|
Apr 25, 2026 |
|
Apr 23, 2026 | Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss
|
Apr 24, 2026 |
|
Apr 21, 2026 | Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T
|
Apr 22, 2026 |
|
Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus
|
Apr 21, 2026 |
|
Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO
|
Apr 21, 2026 |
|
Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'
|
Apr 17, 2026 |
|
Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise
|
Apr 16, 2026 |
|
Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal
|
Apr 14, 2026 |
|
Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win
|
Apr 13, 2026 |
|
Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo; Gilead's $3.15B Tubulis ADC Acquisition
|
Apr 09, 2026 |
|
Apr 07, 2026 | Pharma Tariffs Hit 100% with Major Loopholes; Gilead's $3.15B Tubulis ADC Deal
|
Apr 08, 2026 |
|
Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet
|
Apr 08, 2026 |
|
Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff
|
Apr 06, 2026 |
|
Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree
|
Apr 04, 2026 |
|
Apr 02, 2026 | Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved
|
Apr 03, 2026 |
|
Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials
|
Apr 02, 2026 |
|
Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026
|
Apr 01, 2026 |
|
Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data
|
Mar 31, 2026 |
|
Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026
|
Mar 30, 2026 |
|
Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals
|
Mar 28, 2026 |
|
Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati
|
Mar 27, 2026 |
|
Mar 25, 2026 | Merck's $6.7B Terns Acquisition for CML Drug TERN-701
|
Mar 26, 2026 |
|
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
|
Mar 25, 2026 |
|
Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal
|
Mar 23, 2026 |
|
Mar 22, 2026 | Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed
|
Mar 23, 2026 |
|
Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma
|
Mar 21, 2026 |
|
Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days
|
Mar 20, 2026 |
|
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
|
Mar 18, 2026 |
|
Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%
|
Mar 18, 2026 |
|
Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies
|
Mar 17, 2026 |
|
Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc
|
Mar 16, 2026 |
|
Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval
|
Mar 14, 2026 |
|
Mar 12, 2026 | Ultragenyx Gene Therapy Hits Phase 3 Endpoint; Lilly's $3B China Bet; LAG-3 Oncology Setback
|
Mar 13, 2026 |
|
The AI Reckoning — Episode 4: Who Wins
|
Mar 12, 2026 |
|
Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi
|
Mar 12, 2026 |
|
Mar 10, 2026 | BioNTech's co-founders just walked away
|
Mar 11, 2026 |
|
Mar 09, 2026 | Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval
|
Mar 10, 2026 |
|
The AI Reckoning — Episode 3: The Agentic Enterprise
|
Mar 09, 2026 |
|
Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T Bet; Servier Acquires Day One for $2.5B
|
Mar 09, 2026 |
|
Mar 06, 2026 | FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet
|
Mar 07, 2026 |
|
Mar 5, 2026 | Theravance Phase 3 CYPRESS Failure Triggers 50% Workforce Cut, Science CoRaises $230M for Retinal BCI + Sotyktu PsA PDUFA Tomorrow
|
Mar 06, 2026 |
|
Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement, FDA Fires 30 GLP-1 Compounding Warning Letters + Sotyktu PsA PDUFA Friday
|
Mar 06, 2026 |
|
Special Series| AI Reckoning Ep 2: From Molecule to Market — 173 AI Drugs in Trials, But Phase 2 Data Tells a Different Story
|
Mar 05, 2026 |
|
Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing Bet, Sotyktu PsA PDUFA Friday, Orforglipron Race Begins
|
Mar 03, 2026 |
|
Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer
|
Mar 03, 2026 |
|
Mar 1, 2026 | CagriSema Week of Reckoning: Analysts Revise, Novo Regroups | YUVIWEL Approved + PRV Voucher | Weekend Edition
|
Mar 03, 2026 |
|
Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3
|
Mar 03, 2026 |
|
Special Series| AI Reckoning Ep 1: The Reckoning — 5% of Pharma Has AI Advantage, 95% Still Running Pilots
|
Mar 02, 2026 |